CY1110771T1 - Αλατα και πολυμορφα μιας πυρρολο-υποκατεστημενης ινδολινονικης ενωσης - Google Patents

Αλατα και πολυμορφα μιας πυρρολο-υποκατεστημενης ινδολινονικης ενωσης

Info

Publication number
CY1110771T1
CY1110771T1 CY20101100810T CY101100810T CY1110771T1 CY 1110771 T1 CY1110771 T1 CY 1110771T1 CY 20101100810 T CY20101100810 T CY 20101100810T CY 101100810 T CY101100810 T CY 101100810T CY 1110771 T1 CY1110771 T1 CY 1110771T1
Authority
CY
Cyprus
Prior art keywords
salts
pyrrolo
indolinonic
polymorphes
union
Prior art date
Application number
CY20101100810T
Other languages
Greek (el)
English (en)
Inventor
Andrei Blasko
Qingwu Jin
Qun Lu
Michael Anthony Mauragis
Dian Song
Brenda Sue Vonderwell
Original Assignee
Pharmacia & Upjohn Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company Llc filed Critical Pharmacia & Upjohn Company Llc
Publication of CY1110771T1 publication Critical patent/CY1110771T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CY20101100810T 2003-10-02 2010-09-03 Αλατα και πολυμορφα μιας πυρρολο-υποκατεστημενης ινδολινονικης ενωσης CY1110771T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50810403P 2003-10-02 2003-10-02
EP04769435A EP1670785B1 (en) 2003-10-02 2004-09-20 Salts and polymorphs of a pyrrole-substituted indolinone compound

Publications (1)

Publication Number Publication Date
CY1110771T1 true CY1110771T1 (el) 2015-06-10

Family

ID=34421700

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100810T CY1110771T1 (el) 2003-10-02 2010-09-03 Αλατα και πολυμορφα μιας πυρρολο-υποκατεστημενης ινδολινονικης ενωσης

Country Status (25)

Country Link
US (1) US7247627B2 (enExample)
EP (1) EP1670785B1 (enExample)
JP (1) JP4933259B2 (enExample)
KR (2) KR20060058728A (enExample)
CN (1) CN100432072C (enExample)
AR (1) AR047762A1 (enExample)
AT (1) ATE473223T1 (enExample)
AU (1) AU2004277464B2 (enExample)
BR (1) BRPI0415022A (enExample)
CA (1) CA2540639C (enExample)
CY (1) CY1110771T1 (enExample)
DE (1) DE602004028028D1 (enExample)
DK (1) DK1670785T3 (enExample)
ES (1) ES2348623T3 (enExample)
IL (1) IL174414A (enExample)
MX (1) MXPA06003661A (enExample)
NO (1) NO20061246L (enExample)
NZ (1) NZ546001A (enExample)
PL (1) PL1670785T3 (enExample)
PT (1) PT1670785E (enExample)
RU (1) RU2319702C2 (enExample)
SI (1) SI1670785T1 (enExample)
TW (1) TW200524921A (enExample)
WO (1) WO2005033098A1 (enExample)
ZA (1) ZA200602691B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
CA2602316A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
CN101267824A (zh) * 2005-09-20 2008-09-17 辉瑞产品公司 使用酪氨酸激酶抑制剂的治疗剂型和方法
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
KR101428833B1 (ko) * 2007-04-04 2014-08-08 오츠카 가가쿠 가부시키가이샤 티탄산칼륨, 그의 제조 방법, 마찰재 및 수지 조성물
KR101129088B1 (ko) * 2008-09-17 2012-03-23 노파르티스 아게 N-[6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일]-2-메틸-4'-(트리플루오로메톡시)[1,1'-비페닐]-3-카르복스아미드의 염
RU2430361C1 (ru) * 2010-07-05 2011-09-27 Государственное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет им. В.Ф. Войно-Ясенецкого Министерства здравоохранения и социального развития Российской Федерации" Способ прогнозирования риска развития диабетической ретинопатии при сахарном диабете типа 2 у якутов
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US9851313B2 (en) * 2015-03-03 2017-12-26 Panalytical B.V. Quantitative X-ray analysis—ratio correction

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1575936A3 (ru) * 1986-04-10 1990-06-30 Е.И.Дюпон Де Немур Энд Ко.(Фирма) Способ получени 3,3-дизамещенных индолин-2-ионов или их солей
US5534522A (en) * 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
SI1419151T1 (sl) 2001-08-15 2014-04-30 Pharmacia & Upjohn Company Llc Kristali, ki vključujejo sol jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, postopki za njihovo pripravo in sestavki le-teh
YU67702A (sh) 2001-09-28 2004-12-31 Pfizer Products Inc. Postupak za dobijanje alkansulfonil piridina
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
JP2005528344A (ja) 2002-02-15 2005-09-22 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー インドリノン誘導体の製造法
PY0323128A (es) * 2002-09-10 2012-12-03 Pharmacia Italia Spa Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas

Also Published As

Publication number Publication date
SI1670785T1 (sl) 2010-10-29
JP4933259B2 (ja) 2012-05-16
HK1093068A1 (zh) 2007-02-23
WO2005033098A9 (en) 2006-05-26
NO20061246L (no) 2006-03-29
CN100432072C (zh) 2008-11-12
RU2006110541A (ru) 2006-08-27
KR20080007520A (ko) 2008-01-21
US7247627B2 (en) 2007-07-24
WO2005033098A8 (en) 2006-04-20
MXPA06003661A (es) 2006-06-05
ZA200602691B (en) 2007-06-27
IL174414A0 (en) 2008-02-09
US20050118255A1 (en) 2005-06-02
CN1863796A (zh) 2006-11-15
CA2540639A1 (en) 2005-04-14
DK1670785T3 (da) 2010-10-18
IL174414A (en) 2011-12-29
ATE473223T1 (de) 2010-07-15
WO2005033098A1 (en) 2005-04-14
ES2348623T3 (es) 2010-12-09
PL1670785T3 (pl) 2010-12-31
PT1670785E (pt) 2010-09-16
EP1670785A1 (en) 2006-06-21
RU2319702C2 (ru) 2008-03-20
AU2004277464B2 (en) 2010-07-08
NZ546001A (en) 2009-09-25
JP2007507482A (ja) 2007-03-29
BRPI0415022A (pt) 2006-11-28
KR20060058728A (ko) 2006-05-30
CA2540639C (en) 2010-08-31
DE602004028028D1 (de) 2010-08-19
AU2004277464A1 (en) 2005-04-14
AR047762A1 (es) 2006-02-22
TW200524921A (en) 2005-08-01
EP1670785B1 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
CY1119077T1 (el) Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων
UA99129C2 (ru) Производные оксадиазола и их применение в качестве потенциирующих средств рецепторов глутамата
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
CL2011000957A1 (es) Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer.
UA107175C2 (uk) Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
SE0203713D0 (sv) Novel compounds
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
BR122013025375B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
CY1111603T1 (el) Παραγωγα benzimidazole και η χρηση τους για την τροποποιηση της συνθεσης ληπτη gabaa
NO20083584L (no) Bensoyl-piperidin derivater som 5HT2/D3 modulatorer
EA201000558A1 (ru) Производные имидазола
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
EA200970192A1 (ru) Производные 5,6-бисарил-2-пиридин-карбоксамида, их получение и их применение в терапии в качестве антагонистов рецепторов уротензина ii
EA201270302A1 (ru) Безводные формы производных пиридина
EA200700367A1 (ru) Новые производные 4-бензилиденпиперидина
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
NO20081207L (no) Isoquinolines as IGF-1R inhibitors
EA200500191A1 (ru) Кристаллический 2,5-дион-3-(1-метил-1h-индол-3-ил)-4-[1-(пиридин-2-илметил)пиперидин-4-ил]-1h-индол-3-ил]-1h-пирролмоногидрохлорид
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten